– Hematopoietic Stem cell mobilization by Using Ara-C
– NK activity in Hematologic malignancies
– Distribution of NK cell and MSC after Intravenous infusion
– Prevention of mucositis in HSCT patients
– Belantamab mafadotin in Relapsed/Refractory MM
– Tafasitamab in Relapsed/Refractory DLBCL
– Mosunetuzumab in Relapsed/Refractory DLBCL
– Odronextamab in Relapsed/Refractory DLBCL
– CAR T-cell therapy in Double hit or double expressor DLBCL
– CAR T-cell therapy in Relapsed/Refractory B-ALL